527 related articles for article (PubMed ID: 33854395)
1. Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine.
Helms JM; Ansteatt KT; Roberts JC; Kamatam S; Foong KS; Labayog JS; Tarantino MD
J Blood Med; 2021; 12():221-224. PubMed ID: 33854395
[TBL] [Abstract][Full Text] [Related]
2. Severe romiplostim-induced rebound thrombocytopenia after splenectomy for refractory ITP.
Choe MJ; Packer CD
Ann Pharmacother; 2015 Jan; 49(1):140-4. PubMed ID: 25325908
[TBL] [Abstract][Full Text] [Related]
3. First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine - case report.
Osmanodja B; Schreiber A; Schrezenmeier E; Seelow E
BMC Nephrol; 2021 Dec; 22(1):411. PubMed ID: 34895163
[TBL] [Abstract][Full Text] [Related]
4. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
Sato K; Anayama M; Sumi M; Kobayashi H
Rinsho Ketsueki; 2021; 62(12):1688-1693. PubMed ID: 35022338
[TBL] [Abstract][Full Text] [Related]
5. Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia.
Ruzicka M; Wurm S; Lindner L; Dreyling M; von Bergwelt-Baildon M; Boeck S; Giessen-Jung C; Milani V; Stemmler JH; Subklewe M; Weigert O; Spiekermann K
Infection; 2023 Feb; 51(1):231-238. PubMed ID: 36195695
[TBL] [Abstract][Full Text] [Related]
6. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
Podstawka J; Wall E; Bolster L; Patterson JM; Goodyear MD; Rydz N; Sun HL
Thromb Res; 2022 Dec; 220():5-11. PubMed ID: 36257098
[TBL] [Abstract][Full Text] [Related]
8. Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination.
Jacobs JW; Booth GS; Adkins BD
Ann Hematol; 2023 Apr; 102(4):955-959. PubMed ID: 36795118
[TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination.
Baba Y; Sakai H; Kabasawa N; Harada H
Intern Med; 2022 Jun; 61(12):1891-1895. PubMed ID: 35400701
[TBL] [Abstract][Full Text] [Related]
10. Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist.
Osman ME
Sudan J Paediatr; 2012; 12(2):60-4. PubMed ID: 27493347
[TBL] [Abstract][Full Text] [Related]
11. Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study.
Åkesson A; Bussel JB; Martin M; Blom AM; Klintman J; Ghanima W; Zetterberg E; Garabet L
Platelets; 2023 Dec; 34(1):2159019. PubMed ID: 36636835
[TBL] [Abstract][Full Text] [Related]
12. Successful resection of intrahepatic cholangiocarcinoma with idiopathic thrombocytopenic purpura using thrombopoietin receptor agonist: a case report.
Hoshino K; Harimoto N; Muranushi R; Araki K; Yamanaka T; Hagiwara K; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Yokobori T; Shirabe K
Surg Case Rep; 2019 Apr; 5(1):56. PubMed ID: 30969381
[TBL] [Abstract][Full Text] [Related]
13. Severe case of refractory immune thrombocytopenic purpura requiring splenectomy after the COVID-19 vaccine.
Koilpillai S; Dominguez B; Khan A; Carlan S
BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35725277
[TBL] [Abstract][Full Text] [Related]
14. A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.
Kim G; Choi EJ; Park HS; Lee JH; Lee JH; Lee KH
J Korean Med Sci; 2021 Nov; 36(43):e306. PubMed ID: 34751013
[TBL] [Abstract][Full Text] [Related]
15. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study.
Cooper N; Scully M; Percy C; Nicolson PLR; Lowe G; Bagot CN; Thachil J; Grech H; Nokes T; Hill QA; Bradbury C; Talks K; Dutt T; Evans G; Pavord S; Wexler S; Charania A; Collington SJ; Ervin A; Ramscar N; Provan D
Br J Haematol; 2024 Mar; ():. PubMed ID: 38429869
[TBL] [Abstract][Full Text] [Related]
16. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
[TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
Kapur R; Aslam R; Speck ER; Rebetz JM; Semple JW
Platelets; 2020; 31(3):399-402. PubMed ID: 31146647
[TBL] [Abstract][Full Text] [Related]
18. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
Gao Y; Gong M; Zhang C; Kong X; Ma Y
Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007
[TBL] [Abstract][Full Text] [Related]
19. Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia.
Al-Jafar H; Giagounidis A; El-Rashaid K; Al-Ali M; Hakim AA
Ann Pharmacother; 2012 Nov; 46(11):e31. PubMed ID: 23115229
[TBL] [Abstract][Full Text] [Related]
20. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
